Literature DB >> 24005975

Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange.

Victoria Louise Reid1, Adam Mullan, Lars-Peter Erwig.   

Abstract

Atypical haemolytic uraemic syndrome (aHUS), unlike typical HUS is due to complement dysregulation. At least one abnormality of the complement system can be identified in 70% of patients. aHUS is associated with a poor prognosis with 25% mortality and 50% progress to end-stage renal disease. Genetic abnormalities in the complement system, proteins including CFH, CFI, CFB, C3, CFHR1/3 and MCP (CD46) lead to uncontrolled complement activation in aHUS. We presented the second reported case of aHUS associated with a heterozygous c.191G > T mutation in exon 2 of MCP who responded rapidly to plasma exchange.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24005975      PMCID: PMC3794262          DOI: 10.1136/bcr-2013-200980

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  What's new in haemolytic uraemic syndrome?

Authors:  Sally Johnson; C Mark Taylor
Journal:  Eur J Pediatr       Date:  2008-06-25       Impact factor: 3.183

Review 2.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

Review 3.  Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.

Authors:  Anna Richards; M Kathryn Liszewski; David Kavanagh; Celia J Fang; Elizabeth Moulton; Veronique Fremeaux-Bacchi; Giuseppe Remuzzi; Marina Noris; Timothy H J Goodship; John P Atkinson
Journal:  Mol Immunol       Date:  2006-08-01       Impact factor: 4.407

4.  Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases.

Authors:  Theresa Kwon; Alexandre Belot; Bruno Ranchin; Véronique Baudouin; Véronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Pierre Cochat; Chantal Loirat
Journal:  Nephrol Dial Transplant       Date:  2009-04-17       Impact factor: 5.992

5.  Non-enteropathic hemolytic uremic syndrome: causes and short-term course.

Authors:  Alex R Constantinescu; Martin Bitzan; Lynne S Weiss; Erica Christen; Bernard S Kaplan; Avital Cnaan; Howard Trachtman
Journal:  Am J Kidney Dis       Date:  2004-06       Impact factor: 8.860

Review 6.  Hemolytic uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

Review 7.  Atypical hemolytic uremic syndrome.

Authors:  Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Orphanet J Rare Dis       Date:  2011-09-08       Impact factor: 4.123

  7 in total
  3 in total

Review 1.  Current treatment of atypical hemolytic uremic syndrome.

Authors:  Bernard S Kaplan; Rebecca L Ruebner; Joann M Spinale; Lawrence Copelovitch
Journal:  Intractable Rare Dis Res       Date:  2014-05

2.  Thrombotic microangiopathy with mild renal involvement and profound thrombocytopenia: not all roads lead to thrombotic thrombocytopenic purpura.

Authors:  Victor Milon; Nicolas Fage; Fanny Guibert; Véronique Frémeaux-Bacchi; Jean-François Augusto; Benoit Brilland
Journal:  J Nephrol       Date:  2022-03-22       Impact factor: 3.902

Review 3.  Complement regulator CD46: genetic variants and disease associations.

Authors:  M Kathryn Liszewski; John P Atkinson
Journal:  Hum Genomics       Date:  2015-06-10       Impact factor: 4.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.